Caregivers' Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study

被引：11
作者：
Marshall, Jade [1 ]
Skrobanski, Hanna [2 ]
Moore-Ramdin, Lisa [1 ]
Kornalska, Klaudia [2 ]
Swinburn, Paul [2 ]
Bowditch, Sally [1 ,3 ]
机构：
[1] Jazz Pharmaceut Inc, London, England
[2] Acaster Lloyd Consulting Ltd, London, England
[3] Jazz Pharmaceut Inc, 1 Cavendish Pl, London W1G 0QF, England
来源：
JOURNAL OF CHILD NEUROLOGY | 2023年
关键词：
antiseizure drugs; behavior; epilepsy; quality of life; seizures; PATIENT-REPORTED OUTCOMES; OF-LIFE; OPEN-LABEL; COMORBIDITIES; SEIZURES; TRIAL; EXPERIENCE; MANAGEMENT; MORTALITY; EPILEPSY;
D O I：
10.1177/08830738231185241
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Objective: To increase understanding of the impact of cannabidiol (CBD) on outcomes beyond seizure control among individuals with Dravet syndrome or Lennox-Gastaut syndrome. Methods: Qualitative interviews were conducted with caregivers of individuals with Dravet syndrome or Lennox-Gastaut syndrome treated with plant-derived, highly purified CBD medicine (Epidiolex in the USA; Epidyolex in Europe; 100 mg/mL oral solution). Symptoms and impacts of Dravet syndrome and Lennox-Gastaut syndrome on individuals were explored, as were the effects of CBD. Data were analyzed using thematic analysis. Results: Twenty-one caregivers of individuals with Dravet syndrome (n = 14) and Lennox-Gastaut syndrome (n = 7) aged 4-22 years participated. Health-related quality of life improvements associated with CBD included cognitive function, communication, behavior, mobility, and participation in daily activities. Seizure frequency reduction was commonly reported (n = 12), resulting in caregivers having greater freedom and family life being less disrupted. Adverse events were reported by 10 caregivers. Conclusion: In addition to reduced seizure frequency, CBD may have a wide range of beneficial effects beyond seizure control that warrant further investigation.
引用
收藏
页码：394 / 406
页数：13
相关论文
共 50 条
[41]   Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Lennox-Gastaut Syndrome (LGS) in an Open-Label Extension (OLE) Trial (GWPCARE5) [J].
Perry, M. ;
Patel, A. ;
Gil-Nagel, A. ;
Chin, R. ;
Mitchell, W. ;
Weinstock, A. ;
VanLandingham, K. .
ANNALS OF NEUROLOGY, 2019, 86 :S76-S77
[42]   A quantitative cross-sectional study of the burden of caring for patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex-associated epilepsy in Japan [J].
Lopresti, Michael ;
Igarashi, Ataru ;
Sonohara, Yaoki ;
Bowditch, Sally .
EPILEPSY & BEHAVIOR, 2024, 154
[43]   Is adjunctive Cannabidiol effective in controlling seizures for adult patients with Lennox-Gastaut Syndrome? - A single centre long term follow up study [J].
Elbadri, Maha ;
Bose, Smriti ;
Elkider, Mohammed ;
Hayton, Tom ;
McCorry, Dougall ;
Sumangala, Salini ;
Wysota, Barbara ;
Samarasekera, Shanika .
EPILEPSY & BEHAVIOR, 2024, 157
[44]   ADDITION OF CANNABIDIOL TO CURRENT ANTIEPILEPTIC THERAPY REDUCES DROP SEIZURES IN CHILDREN AND ADULTS WITH TREATMENT - RESISTANT LENNOX-GASTAUT SYNDROME [J].
Ostrovsky, Daniel A. ;
Ehrlich, Alan .
EXPLORE-THE JOURNAL OF SCIENCE AND HEALING, 2018, 14 (04) :311-313
[45]   Treatment with Cannabidiol (CBD) Significantly Reduces Drop and Total Seizure Frequency in Lennox-Gastaut Syndrome (LGS): Results of a Multicenter, Randomized, Double-blind, Placebo Controlled Trial (GWPCARE4) [J].
Joshi, C. ;
Thiele, E. ;
Marsh, E. ;
French, J. .
ANNALS OF NEUROLOGY, 2017, 82 :S293-S293
[46]   Long-term Safety and Efficacy of Cannabidiol (CBD) in Patients with Lennox-Gastaut Syndrome (LGS): Results of the Open-label Extension (OLE) Trial (GWPCARE5) [J].
Thiele, E. ;
Marsh, E. ;
Halford, J. ;
Mazurkiewicz-Beldzinska, M. ;
Gunning, B. ;
Checketts, D. ;
Roberts, C. .
ANNALS OF NEUROLOGY, 2018, 84 :S336-S336
[47]   Case Report: Lennox-Gastaut Epileptic Encephalopathy Responsive to Cannabidiol Treatment Associated With a Novel de novo Mosaic SHANK1 Variant [J].
Paprocka, Justyna ;
Zietkiewicz, Szymon ;
Kosinska, Joanna ;
Kaczorowska, Ewa ;
Ploski, Rafal .
FRONTIERS IN GENETICS, 2021, 12
[48]   HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN TREATMENT IN CRYPTOGENIC WEST AND LENNOX-GASTAUT SYNDROME - AN ADD-ON STUDY [J].
VANENGELEN, BGM ;
RENIER, WO ;
WEEMAES, CMR ;
STRENGERS, PFW ;
BERNSEN, PJH ;
NOTERMANS, SLH .
EUROPEAN JOURNAL OF PEDIATRICS, 1994, 153 (10) :762-769
[49]   Caregivers' Perspectives on the Use of Long-Term Oxygen Therapy for the Treatment of Refractory Breathlessness: A Qualitative Study [J].
Collier, Aileen ;
Breaden, Katrina ;
Phillips, Jane L. ;
Agar, Meera ;
Litster, Caroline ;
Currow, David C. .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2017, 53 (01) :33-39
[50]   Perspectives on Lower Extremity Peripheral Artery Disease: A Qualitative Study of Early Diagnosis and Treatment and the Impact of Health Disparities [J].
Grant, Cori ;
Cuddeback, John K. ;
Alabi, Olamide ;
Hicks, Caitlin W. ;
Sadik, Kay ;
Ciemins, Elizabeth L. .
POPULATION HEALTH MANAGEMENT, 2023, 26 (06) :387-396
12345